CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Gayathri Udyawar
/ Categories: Trending, Markets

Dr Reddy Labs receives EIR for Srikakulam plant

The US drug regulator has issued Establishment Inspection Report to Dr. Reddy's Laboratories' active pharmaceutical ingredient (API) plant in Srikakulam (SEZ), Andhra Pradesh.

 

The audit of the plant was completed by the US Food and Drug Administration (USFDA) in June 2018 with no observations.

 

On the other hand, Dr. Reddy's initiated a voluntary recall of Atorvastatin Calcium tablets in the US market. The cholesterol-lowering tablets was called back through a Class-3 recall after noticing anomalies during out of specifications (OOS) investigations. More than 2,000 bottles of 40 mg tablets were recalled following Failed impurities/degradation specifications -OOS.

 

Reacting to this mix of positive and negative news, the stock of Dr. Reddy's Lab was quoting Rs. 2,452.45 per share, down by Rs. 12.15 or 0.49 per cent at 11:26 hours on Friday. While the BSE Sensex was at 38,297.46, down 39.30 points or 0.10 per cent.

Previous Article Index trend and stocks in action August 24, 2018
Next Article Ashok Leyland Wins Defence Tender
Print
1013 Rate this article:
3.3
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR